Andre Goy, MD, discusses the data presented at the 2018 ASH Annual Meeting for combination lenalidomide plus rituximab, also known as the R<sup>2</sup> regimen, for the treatment of patients with relapsed/recurrent follicular lymphoma.<br />
Andre Goy, MD, chief, division of lymphoma, chairman and director, John Theurer Cancer Center, discusses the data presented at the 2018 ASH Annual Meeting for combination lenalidomide (Revlimid) plus rituximab (Rituxan), also known as the R2regimen, for the treatment of patients with relapsed/recurrent follicular lymphoma.
In this patient population, rituximab monotherapy was standard treatment, but this was not an appealing option for older patients. The data support R2
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
FDA Enforces Partial Hold on Trial of Seclidemstat in MDS/CMML
July 16th 2024Following the report of a serious and unexpected grade 4 adverse effect, a partial clinical hold has been placed on the phase 1 trial evaluating seclidemstat with azacitidine in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Read More